As China emerges as a key player in the global biopharma ecosystem—driven by a surge in novel drug development, innovative technology platforms, and expanding global ambitions—BD&L strategies must evolve accordingly. Expanding into or partnering with China presents unique challenges alongside significant rewards. This session explores how to successfully engage with China by navigating its innovation landscape, regulatory environment, and cultural dynamics to unlock sustainable growth and maximize global impact.
Objectives- Identify key success factors for building effective strategy and synergistic partnership
- Discuss regulatory frameworks, market access considerations, and cultural insights to guide localized, cross-border dealmaking
- Learn from real-world examples of China-focused BD&L collaborations
